retatrutide trial results october 2025 Retatrutide: The Triple Agonist That's Redrawing the Map of Obesity Medicine Retatrutide and the Grey Market:

September 5th, 2025: Research Suggests GLP-1 Medications May Raise Kidney Cancer Risk Amid Growing Litigation A new study published in JAMA Oncology suggests that GLP-1 receptor agonists such as Ozempic and Mounjaro could increase the risk of kidney cancer, despite appearing to lower the risk of certain other cancers

Taking an unregulated version means you bypass the safety monitoring built into clinical programmes

Floating particles suggest either manufacturing contamination (foreign material introduced during lyophilisation) or stopper degradation (rubber fragments dislodged during needle insertion)

The cost of Semaglutide (GLP-1) injections for weight loss typically ranges from $650 to $1,349 per month